Similar articles

• Lamivudine therapy of hepatitis B virus-related liver disease: cirrhosis, posttransplantation recurrence, and de novo infection.

  Bárcena R, Domínguez-Antonaya M, López-Sanromán A, Martínez-Turnes A, Urman J, del Campo S, Moreno N. Bárcena R, et al. Transplant Proc. 1999 Sep;31(6):2457-8. doi: 10.1016/s0041-1345(99)00416-9. Transplant Proc. 1999. PMID: 10500669 No abstract available.
• Prophylaxis and treatment of hepatitis B virus reinfection following liver transplantation.

  Zheng SS, Wu J, Liang TB, Wang WL, Huang DS, Xu X. Zheng SS, et al. Hepatobiliary Pancreat Dis Int. 2002 Aug;1(3):327-9. Hepatobiliary Pancreat Dis Int. 2002. PMID: 14607701
• Lamivudine for hepatitis B in liver transplantation: a single-center experience.

  Malkan G, Cattral MS, Humar A, Al Asghar H, Greig PD, Hemming AW, Levy GA, Lilly LB. Malkan G, et al. Transplantation. 2000 Apr 15;69(7):1403-7. doi: 10.1097/00007890-200004150-00033. Transplantation. 2000. PMID: 10798762
• Lamivudine therapy for severe acute hepatitis B virus infection after renal transplantation: case report and literature review.

  Nakhoul F, Gelman R, Green J, Khankin E, Baruch Y. Nakhoul F, et al. Transplant Proc. 2001 Sep;33(6):2948-9. doi: 10.1016/s0041-1345(01)02265-5. Transplant Proc. 2001. PMID: 11543804 Review. No abstract available.
• Management of patients with decompensated HBV cirrhosis.

  Fontana RJ. Fontana RJ. Semin Liver Dis. 2003 Feb;23(1):89-100. doi: 10.1055/s-2003-37591. Semin Liver Dis. 2003. PMID: 12616454 Review.